loading

Pieris Pharmaceuticals Inc Stock (PIRS) Latest News

pulisher
Nov 20, 2024

PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Marketscreener.com

Nov 20, 2024
pulisher
Nov 18, 2024

Comparing Evelo Biosciences (NASDAQ:EVLO) and Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World

Nov 18, 2024
pulisher
Nov 17, 2024

How To Trade (PIRS) - Stock Traders Daily

Nov 17, 2024
pulisher
Nov 14, 2024

Lynx1 Capital Management LP Adjusts Stake in Pieris Pharmaceuticals Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Pieris Pharmaceuticals: Q3 Earnings Snapshot - The Washington Post

Nov 14, 2024
pulisher
Nov 13, 2024

Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com - Defense World

Nov 13, 2024
pulisher
Nov 06, 2024

(PIRS) Investment Analysis and Advice - Stock Traders Daily

Nov 06, 2024
pulisher
Nov 01, 2024

Pieris Pharmaceuticals: Q2 Earnings Snapshot - Barchart

Nov 01, 2024
pulisher
Oct 28, 2024

Pieris Pharmaceuticals director buys series F preferred stock for $1 By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 28, 2024

Pieris Pharmaceuticals director buys series F preferred stock for $1 - Investing.com

Oct 28, 2024
pulisher
Oct 26, 2024

(PIRS) Technical Data - Stock Traders Daily

Oct 26, 2024
pulisher
Oct 21, 2024

pieris pharmaceuticals, inc. Earnings dates - RTTNews

Oct 21, 2024
pulisher
Oct 17, 2024

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer - The Manila Times

Oct 17, 2024
pulisher
Oct 16, 2024

Learn to Evaluate (PIRS) using the Charts - Stock Traders Daily

Oct 16, 2024
pulisher
Oct 05, 2024

(PIRS) Trading Signals - Stock Traders Daily

Oct 05, 2024
pulisher
Oct 03, 2024

Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations - GlobeNewswire

Oct 03, 2024
pulisher
Sep 27, 2024

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Sees Significant Decrease in Short Interest - Defense World

Sep 27, 2024
pulisher
Sep 25, 2024

New Alzheimer’s Therapy Shows Remarkable Results in Animal Trials - SciTechDaily

Sep 25, 2024
pulisher
Sep 13, 2024

How the (PIRS) price action is used to our Advantage - Stock Traders Daily

Sep 13, 2024
pulisher
Sep 03, 2024

PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire

Sep 03, 2024
pulisher
Aug 21, 2024

Wayne-based Palvella Therapeutics Poised to Go Public Later This Year - VISTA.Today

Aug 21, 2024
pulisher
Aug 19, 2024

Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023) - Yahoo Finance

Aug 19, 2024
pulisher
Aug 17, 2024

We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate - Yahoo Finance

Aug 17, 2024
pulisher
Aug 16, 2024

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc.PIRS - PR Newswire

Aug 16, 2024
pulisher
Aug 16, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders - ForexTV.com

Aug 16, 2024
pulisher
Aug 15, 2024

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of PIRS, ENV, GVP - AccessWire

Aug 15, 2024
pulisher
Aug 13, 2024

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS - ForexTV.com

Aug 13, 2024
pulisher
Aug 13, 2024

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Purchases 3,000 Shares of Stock - Defense World

Aug 13, 2024
pulisher
Aug 12, 2024

Adar1 capital management buys $92k worth of Pieris Pharmaceuticals stock - Investing.com

Aug 12, 2024
pulisher
Aug 06, 2024

(PIRS) Long Term Investment Analysis - Stock Traders Daily

Aug 06, 2024
pulisher
Aug 03, 2024

Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Passes Above 50 Day Moving Average of $10.02 - Defense World

Aug 03, 2024
pulisher
Jul 30, 2024

Global Chemotherapy Induced Anemia Drug Market 2024 Analysis by Top Key Players |SBI Pharmaceuticals Co. Ltd. - The NRI News

Jul 30, 2024
pulisher
Jul 26, 2024

Public Equity Report: Palvella lands on NASDAQ via Pieris merger - BioCentury

Jul 26, 2024
pulisher
Jul 26, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of Shareholders - The Malaysian Reserve

Jul 26, 2024
pulisher
Jul 25, 2024

General Mills, Inc. [GIS] gain 0.57% so far this year. What now? - The DBT News

Jul 25, 2024
pulisher
Jul 25, 2024

Finansavisen - Finansavisen

Jul 25, 2024
pulisher
Jul 24, 2024

Viking Therapeutics stock (VKTX) could hit all time high and here’s why - BP Journal

Jul 24, 2024
pulisher
Jul 24, 2024

Pieris Pharmaceuticals ($PIRS) and Palvella Therapeutics Announce Exciting Merger - BP Journal

Jul 24, 2024
pulisher
Jul 24, 2024

Is today’s surge in Dermata Therapeutics (DRMA) justified ? - BP Journal

Jul 24, 2024
pulisher
Jul 24, 2024

Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders - PR Newswire

Jul 24, 2024
pulisher
Jul 24, 2024

Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings - Benzinga

Jul 24, 2024
pulisher
Jul 24, 2024

PIRS Stock on the Rise: A Promising Investment - The InvestChronicle

Jul 24, 2024
pulisher
Jul 24, 2024

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga

Jul 24, 2024
pulisher
Jul 24, 2024

Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results - Benzinga

Jul 24, 2024
pulisher
Jul 24, 2024

Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today? - InvestorPlace

Jul 24, 2024
pulisher
Jul 24, 2024

Ivey Business School Opens the Market to celebrate Women in Asset Management Program - The Bubble

Jul 24, 2024
$18.94
price down icon 1.35%
$75.45
price up icon 0.87%
$43.39
price up icon 3.19%
$378.13
price up icon 0.30%
$206.16
price up icon 7.31%
$120.72
price up icon 1.84%
Cap:     |  Volume (24h):